Contents

Chapter I  General introduction to tumor immunology and scope of the thesis  9

Part A

Chapter II  Introduction to MHC class II in tumor immunology: prognostic marker and target for immune modulation  27
*Immunobiology* 2006;211:619-25

Chapter III  Class II-associated Invariant Chain peptide expression on myeloid leukemic blasts predict poor clinical outcome  39
*Cancer Research* 2004;64:5546-50

Chapter IV  Down-modulation of Invariant Chain and CLIP expression enhances CD4+ T cell recognition of acute myeloid leukemic blasts  53
Submitted

Chapter V  Aberrant MHC class II antigen presentation is linked to expansion of the activated T cell compartment in B-CLL  73
Submitted

Part B

Chapter VI  Immune mediated autologous cytotoxicity against hematopoietic precursor cells in patients with myelodysplastic syndrome  93
*Haematologica* 2009, in press

Chapter VII  High expression of decoy receptor TRAIL-R3 on AML blasts is associated with poor clinical outcome and induces apoptosis resistance which can be overcome by targeting TRAIL-R2  113
Submitted

Chapter VIII  High *INDO* (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome  133
*Haematologica* 2008;93:1894-1898

Chapter IX  Conclusions, discussion and future perspectives  145

Appendices

Curriculum Vitae  159
List of publications  160
Nederlandse samenvatting voor de leek  163
Dankwoord  167
List of abbreviations  173